ANTIBODIES AND ANTIBODY FRAGMENTS TARGETING SIRP-ALPHA AND THEIR USE IN TREATING HEMATOLOGIC CANCERS

摘要

The invention relates to modulating the SIRPα—CD47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided SIRPα antibodies and antibody fragments, preferably used for treating hematological cancer.

主权项

1. An antibody comprising at least one CDR selected from the group consisting of:a) CDRL1:(SEQ ID NO. 55)S-V-S-S-A;b) CDRL2:(SEQ ID NO. 56)S-A-S-S-L-Y-S;c) CDRL3:(SEQ ID NO. 54)A-V-N-W-V-G-A-L-V;d) CDRH1:(SEQ ID NO. 52)I-S-Y-Y-F-I;e) CDRH2:(SEQ ID NO. 53)S-V-Y-S-S-F-G-Y-T-Y; andf) CDRH3:X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18; wherein:
X1 is F;X2 is T, A or S;X3 is F;X4 is P;X5 is G;X6 is L, H, F, M, Q, R, V, K, T or A;X7 is F, H, I, L or M;X8 is D, E, N, A, S, T or G;X9 is G;X10 is F;X11 is F;X12 is G, R, A, S or T;X13 is A, S, T, G, D, E, K, Y, N or P;X14 is Y, F or H;X15 is L, H, Y or I;X16 is G;X17 is S, A, G or P; andX18 is L.